These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 23485165)

  • 21. [Validation and clinical application of MammaPrint
    Sánchez-Forgach ER; Carpinteyro-Espín U; Alemán-Áviles JA; Sánchez-Basurto C
    Cir Cir; 2017; 85(4):320-324. PubMed ID: 27979362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks.
    Roukos DH; Ziogas DE; Katsios C
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1187-95. PubMed ID: 20735306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2011 Aug; 128(3):633-41. PubMed ID: 20803240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
    Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
    Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
    Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy.
    Glück S; de Snoo F; Peeters J; Stork-Sloots L; Somlo G
    Breast Cancer Res Treat; 2013 Jun; 139(3):759-67. PubMed ID: 23756626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MammaPrint Reduces Breast Cancer Overtreatment.
    Cancer Discov; 2016 Jun; 6(6):OF4. PubMed ID: 27095361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH; Cosler LE; Kuderer NM; Hornberger J
    Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance characteristics of the MammaPrint
    Delahaye LJ; Wehkamp D; Floore AN; Bernards R; Van't Veer LJ; Glas AM
    Per Med; 2013 Nov; 10(8):801-811. PubMed ID: 29776281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
    Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
    Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs.
    Geutjes EJ; Tian S; Roepman P; Bernards R
    Breast Cancer Res Treat; 2012 Feb; 131(3):809-18. PubMed ID: 21465168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer].
    Gerson Cwilich R; Alban de la Torre LF; Villalobos Prieto A; Serrano Olvera JA
    Gac Med Mex; 2012; 148(2):117-24. PubMed ID: 22622310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A plea for selective use of the MammaPrint test].
    de Boer M; Voogd AC; Tjan-Heijnen VC
    Ned Tijdschr Geneeskd; 2017; 161():D1160. PubMed ID: 28401819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
    Shimizu H; Horimoto Y; Arakawa A; Sonoue H; Kurata M; Kosaka T; Nakai K; Himuro T; Tokuda E; Takahashi Y; Taira F; Ito M; Abe I; Senuma K; Stork-Sloots L; de Snoo F; Saito M
    Breast Care (Basel); 2015 Apr; 10(2):118-22. PubMed ID: 26195940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Validation and clinical application of MammaPrint® in patients with breast cancer].
    Cuadros M; Llanos A
    Med Clin (Barc); 2011 May; 136(14):627-32. PubMed ID: 20416899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.